Approximately 20-30% of cases of adult ALL are Philadelphia chromosome positive (Ph þ ). 1, 2 Owing to the dismal outcome of Ph þ ALL with chemotherapy, allogeneic hematopoietic SCT (HSCT) is routinely offered as it is considered to be the only potentially curative therapy. 3 The usual therapeutic intervention in patients with ALL relapsing after allogeneic HSCT is donor lymphocyte infusion or a second allograft, but even with these treatments benefits to the patients are very limited.
The role of imatinib as the first molecularly targeted therapy to reduce relapse incidence after HSCT is significant, but a number of patients eventually relapse owing to the development of mutations in the ABL kinase domain that reduce sensitivity to imatinib. 4 To override imatinib resistance and mutations, second-generation tyrosine kinase inhibitors such as dasatinib and AMN107 have been designed. These new compounds have shown promising clinical activity in imatinib-resistant patients with refractory Ph þ ALL and offer new treatment options for patients who do not achieve an optimal response to imatinib therapy. 4 We report conversion to full donor-type chimerism and achievement of CR in a patient with Ph þ ALL relapsing after HSCT after dasatinib therapy.
In October 2007, a 38-year-old man was diagnosed to have pre-B ALL with a leukocyte count of 23.4 Â 10 9 /l. The BM aspirate was markedly hypercellular with 73% leukemic blasts. CSF was normal. The patient was treated with combination induction chemotherapy. 5 On day 28 of induction therapy, blast cells occupied 450% of his BM and cytogenetic analysis revealed a t(9;22)(q34;q11.2) in all 20 metaphases analyzed. RT-PCR demonstrated the e1a2 rearrangement of BCR-ABL with a breakpoint in the minor breakpoint cluster region (mBCR), which is frequently seen in Ph þ ALL patients. He was treated with hyperCVAD and 400 mg imatinib mesylate per day. BM aspiration after the first cycle revealed 1.2% blasts. After the second cycle, the mBCR e1a2 fusion transcript was still detected by RT-PCR.
In March 2008, the patient underwent allogeneic HSCT from his HLA-identical brother after BU and melphalan. GVHD prophylaxis consisted of MTX and cyclosporine. Eventually, he developed mild GVHD with cutaneous and gastrointestinal tract involvement, which resolved spontaneously. Hematologic relapse occurred at 7 months, with blood and BM blast counts of 50 and 90%, respectively. Dasatinib 140 mg daily was initiated in combination with VCR once a week and dexamethasone daily. Two months later, BM examinations showed the absence of any BM blasts and proved negative for bcr-abl by RT-PCR. VCR and dexamethasone were discontinued, and the patient was maintained on the same dose of dasatinib. STR-based chimerism studies on peripheral blood leukocytes showed reconstitution with 100% donor cells in March 2009, and full chimerism has been maintained since then. The patient is doing well and is in a persistent molecular remission after 8 months on therapy.
There have only been a few reports describing the utility of dasatinib in patients with ALL relapsing after HSCT. Of note in our case are the durability of response, its association with conversion to full donor chimerism without significant GVHD and the ability of the patient to tolerate standard doses of dasatinib without any toxicity.
In 2007, Reddiconto et al. 6 reported the case of a Ph þ ALL patient who received salvage therapy with dasatinib and achieved a durable molecular remission for more than 8 months after the failure of both imatinib-based treatment and subsequent allogeneic cord blood transplantation from an unrelated donor. Recently, Quinta´s-Cardama and Cortes 7 reported a full chimerism and complete molecular response (22 weeks) to dasatinib in a single patient with imatinib-resistant bcr-abl-positive leukemia, who, however, experienced CNS relapse of his disease thereafter and died.
Evidence from an in vitro study indicated that dasatinib has a 325-fold greater potency than imatinib at inhibiting non-mutant bcr-abl, 8 and a 100-fold greater potency in the 14-15 mutations that arise in imatinib resistance. 9, 10 Dasatinib is also known to induce the growth arrest of leukemic clones carrying most of the imatinib-resistant bcr-abl kinase domain mutations. 10 In light of its clinical benefits as a salvage therapy, we believe that dasatinib may be a worthwhile option to prevent relapse after HSCT. 
